Gewinn- und Verlustrechnung von Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc. (NYSE: TMO - Get Free Report)'s stock price hit a new 52-week high on Tuesday. The company traded as high as $694.33 and last traded at $678.8880, with a volume of 218570 shares. The stock had previously closed at $676.76. Trending Headlines about Thermo Fisher Scientific Here are the key news stories

Globus Medical, Intuitive Surgical and Thermo Fisher Scientific have been highlighted in this Industry Outlook article.

MILAN--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, is expanding its drug development, manufacturing, and clinical capabilities to help pharmaceutical and biotechnology companies navigate increasingly complex paths to commercialization, reduce friction, and maintain momentum. The company will showcase these new and expanded capabilities at CPHI Milan 2026, Oct. 6-8. Among the new offerings is OSD Express, a defined solution designed to increase predictability.

Thermo Fisher Scientific, the laboratory-equipment and life-sciences services company (TMO), joined JPMorgan's (JPM) October growth selections, with shares up a

Park National Corp OH grew its holdings in Thermo Fisher Scientific Inc. (NYSE: TMO) by 1,067.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,329 shares of the medical research company's stock after purchasing an additional 5,787

Rockland Trust Co. decreased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE: TMO) by 46.3% during the third quarter, according to its most recent filing with the SEC. The firm owned 34,723 shares of the medical research company's stock after selling 29,916 shares during the period. Rockland Trust Co.'s holdings in

Ferguson Wellman Capital Management Inc. raised its holdings in shares of Thermo Fisher Scientific Inc. (NYSE: TMO) by 11.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 86,904 shares of the medical research company's stock after buying an additional

GenAI offers growth opportunities for GMED, ISRG and TMO, but evolving regulations and industry risks are likely to shape adoption.

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced that its strategic collaboration with Precision Health Research, Singapore (PRECISE) and Nanyang Technological University, Singapore (NTU Singapore) has led to the discovery of more than 2,500 previously unreported genetic-protein associations. By combining Thermo Fisher's complementary proteomics technologies with PRECISE-SG100K's large-scale health and genomic data, researchers.

MassMutual Private Wealth and Trust FSB reduced its position in Thermo Fisher Scientific Inc. (NYSE: TMO) by 2.6% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 50,766 shares of the medical research company's stock after selling 1,348 shares